Related Experiment Video
Updated: Apr 6, 2026

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
Published on: April 21, 2015
Platelet perturbation to ciprofloxacin exacerbates IBD through regulation of HLA DR on CD14⁻CD16⁺ monocytes
Lili Wang1, Lintao Dong2, Jingping Hu2
1Guyuan People's Hospital, Guyuan, Ningxia, China.
Abstract:
Inflammatory bowel disease (IBD) is a chronic and relapsing disorder influenced by immune dysfunction and other systemic factors. However, the exact pathogenesis of IBD remains incompletely understood. In addition to the traditionally recognized immune dysregulation, recent studies have suggested that the hematopoietic system also plays an important role in the development and progression of IBD. In this study, we applied mediation Mendelian randomization analysis to systematically investigate the role of blood cell perturbation phenotypes and immune cells in IBD pathogenesis. A total of 91 human blood cell perturbation phenotypes were used as exposures, IBD cases from Finnish and European populations served as outcomes, and 731 immune cell phenotypes were assessed as potential mediators. Our results revealed that HLA-DR expression on CD14⁻CD16⁺ monocytes exerts a protective effect by reducing the risk of IBD. However, platelet disturbance in response to ciprofloxacin downregulates HLA-DR expression on these monocytes, thereby weakening this protective effect and increasing disease risk. In conclusion, this study systematically explores a potential mechanism by which platelet perturbation contributes to the development and progression of IBD through immune cell mediation, using mediation Mendelian randomization.
More Related Videos
07:34Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
Published on: December 16, 2021
09:44Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids